|
2025 Journal Article AUSTRALIAN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA FREQUENTLY FAIL ELIGIBILITY CRITERIA FOR LANDMARK AND REGISTRATION CLINICAL TRIALSGoodall, E., Palmer, J., Martynchyk, A., Waters, N., Swain, F., Marconi, T., Giang, T. B., Brennan, J., Gregory, G., Cheah, C., Keane, C. and Hawkes, E. (2025). AUSTRALIAN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA FREQUENTLY FAIL ELIGIBILITY CRITERIA FOR LANDMARK AND REGISTRATION CLINICAL TRIALS. Hematological Oncology, 43 (S3) e626_70096. doi: 10.1002/hon.70096_626 |
|
2025 Journal Article TREATMENT OF NEWLY‐DIAGNOSED FOLLICULAR LYMPHOMA WITH RITUXIMAB, GOLCADOMIDE +/‐ NIVOLUMAB‐ INTERIM ANALYSIS OF THE PHASE II TOP‐FLOR STUDYMartynchyck, A., Chong, G., Barraclough, A., Ratnasingam, S., Marconi, T., Palmer, J. B., Keane, C., Lee, S. T. B., Scott, A. M., Romano, A., Churilov, L., Lee, D. and Hawkes, E. A. (2025). TREATMENT OF NEWLY‐DIAGNOSED FOLLICULAR LYMPHOMA WITH RITUXIMAB, GOLCADOMIDE +/‐ NIVOLUMAB‐ INTERIM ANALYSIS OF THE PHASE II TOP‐FLOR STUDY. Hematological Oncology, 43 (S3) e230_70094. doi: 10.1002/hon.70094_230 |
|
2025 Journal Article Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-Dimensional MRIO’Shaughnessy, Jack, Martynchyk, Arina, Lee, Sze Ting, Chong, Geoff, Agrawal, Shivam, Tatarczuch, Maciej, Azryn, Nariza Alysa, Gregory, Gareth P, Churilov, Leonid, Wang, Michael, Keane, Colm and Hawkes, Eliza A (2025). Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-Dimensional MRI. Neuro-Oncology Advances, 7 (1) vdaf090. doi: 10.1093/noajnl/vdaf090 |
|
2025 Journal Article Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' studyBarraclough, Allison, Lee, Sze Ting, Burgess, Melinda, Churilov, Leonid, Chong, Geoffrey, Lee, Denise, Gilbertson, Michael, Fancourt, Tineke, Manos, Kate, Ritchie, David, Koldej, Rachel M, Scott, Andrew, Keane, Colm and Hawkes, Eliza A (2025). Nivolumab and rituximab in treatment naive follicular lymphoma: the phase II '1st FLOR' study. Blood Advances, 9 (6), 1432-1441. doi: 10.1182/bloodadvances.2024015487 |
|
2024 Journal Article Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMacManus, Michael P., Seymour, John F., Tsang, Hennes, Fisher, Richard, Keane, Colm, Sabdia, Muhammed B., Law, Soi C., Gunawardana, Jay, Nath, Karthik, Kazakoff, Stephen H., Marques-Piubelli, Mario L., Duenas, Daniela E., Green, Michael R., Roos, Daniel, O'Brien, Peter, McCann, Andrew, Tsang, Richard, Davis, Sidney, Christie, David, Cheah, Chan, Amanuel, Benhur, Cochrane, Tara, Butler, Jason, Johnston, Anna, Shanavas, Mohamed, Li, Li, Vajdic, Claire, Kridel, Robert, Shelton, Victoria ... Tobin, Joshua W. D. (2024). Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma. eBioMedicine, 110 105468, 1-13. doi: 10.1016/j.ebiom.2024.105468 |
|
2024 Journal Article Magrolimab plus rituximab with/without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphomaMaakaron, Joeseph, Asch, Adam S., Popplewell, Leslie, Collins, Graham P., Flinn, Ian W., Ghosh, Nilanjan, Keane, Colm, Ku, Matthew, Mehta, Amitkumar, Roschewski, Mark, Hacohen-Kleiman, Gal, Huo, Yanan, Zhang, Yi, Renard, Camille, Smith, Sonali M. and Advani, Ranjana H. (2024). Magrolimab plus rituximab with/without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 8 (22), 5864-5874. doi: 10.1182/bloodadvances.2024013338 |
|
2024 Journal Article Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammationMcCulloch, Timothy R., Rossi, Gustavo R., Alim, Louisa, Lam, Pui Yeng, Wong, Joshua K. M., Coleborn, Elaina, Kumari, Snehlata, Keane, Colm, Kueh, Andrew J., Herold, Marco J., Wilhelm, Christoph, Knolle, Percy A., Kane, Lawrence, Wells, Timothy J. and Souza-Fonseca-Guimaraes, Fernando (2024). Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation. Nature Communications, 15 (1) 9871, 1-16. doi: 10.1038/s41467-024-54232-y |
|
2024 Journal Article Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphomaGunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Snell, Cameron, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Shanavas, Mohamed, Blyth, Emily, Steidl, Christian, Savage, Kerry, Farinha, Pedro ... Gandhi, Maher K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology, 99 (11), 2096-2107. doi: 10.1002/ajh.27459 |
|
2024 Journal Article Genetic and immunological features of immune deficiency and dysregulation‐associated lymphoproliferations and lymphomas as a basis for classificationDierickx, Daan, Keane, Colm and Natkunam, Yasodha (2024). Genetic and immunological features of immune deficiency and dysregulation‐associated lymphoproliferations and lymphomas as a basis for classification. Histopathology, 86 (1), 106-118. doi: 10.1111/his.15342 |
|
2024 Journal Article Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyBarraclough, Allison, Agrawal, Shivam, Talaulikar, Dipti, Chong, Geoffrey, Yoo, Edward, Cheah, Chan Y., Franco, Nunzio, Nguyen, Bianca, Mutsando, Howard, Tahir, Fatima, Trotman, Judith, Huang, Jing, Keane, Colm, Lincoln, Mitchel, Cochrane, Tara, Johnston, Anna M., Dickinson, Michael, Opat, Stephen, McQuilten, Zoe K., Wood, Erica M., St George, Gayathri and Hawkes, Eliza A. (2024). Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica, 109 (10), 3338-3345. doi: 10.3324/haematol.2023.284538 |
|
2024 Journal Article Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillanceWight, Joel, Blombery, Piers, Lickiss, Jennifer, Burgess, Melinda, Gould, Clare, Minson, Adrian, Swain, Fiona, Sabdia, Muhammed B., Gandhi, Maher K., Birchley, Andrew, Keane, Colm and Hawkes, Eliza A. (2024). Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance. Haematologica, 109 (9), 3013-3018. doi: 10.3324/haematol.2023.284600 |
|
2024 Journal Article Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectShaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan Y, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoffrey, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A. (2024). Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. eJHaem, 5 (2), 325-332. doi: 10.1002/jha2.870 |
|
2024 Journal Article Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironmentAlim, Louisa F., Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2024). Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Current Opinion in Immunology, 86 102409, 102409. doi: 10.1016/j.coi.2023.102409 |
|
2024 Journal Article Epstein–Barr virus‐associated lymphomas decodedBednarska, Karolina, Chowdhury, Rakin, Tobin, Joshua W. D., Swain, Fiona, Keane, Colm, Boyle, Stephen, Khanna, Rajiv and Gandhi, Maher K. (2024). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology, 204 (2), 415-433. doi: 10.1111/bjh.19255 |
|
2023 Journal Article Prognostic markers within the tumour microenvironment in classical Hodgkin lymphomaMartynchyk, Arina, Chowdhury, Rakin, Hawkes, Eliza A. and Keane, Colm (2023). Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma. Cancers, 15 (21) 5217, 1-21. doi: 10.3390/cancers15215217 |
|
2023 Journal Article Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemiaCass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007 |
|
2023 Journal Article C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patientsBonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology, 21 (1), 77-86. doi: 10.1111/ajco.13993 |
|
2023 Journal Article Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphomaGandhi, Maher K. and Keane, Colm (2023). Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma. Haematologica, 108 (12), 3195-3196. doi: 10.3324/haematol.2023.283392 |
|
2023 Journal Article Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemiaBurgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631 |
|
2023 Journal Article A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphomaGeorge, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078 |
